FDA clears LivaNova aura6000 for moderate to severe sleep apnea

LivaNova’s aura6000 system has secured U.S. FDA premarket approval, giving the company a commercial foothold in the obstructive sleep apnea device market after several years of clinical development. FDA’s approval, dated March 18, 2026, covers adult patients with moderate to severe OSA, with an AHI of 15 to 65, who have failed, don’t tolerate, or aren’t eligible for first-line options such as PAP, oral appliances, or pharmacotherapy. (accessdata.fda.gov)

The approval caps a sequence of milestones that began with FDA clearance in 2021 to study the device clinically, followed by positive OSPREY randomized trial data in 2024 and a completed PMA submission in April 2025. LivaNova reported in November 2024 that OSPREY met its primary safety and efficacy endpoints, then said in May 2025 that it had submitted the PMA and seen a 65% responder rate at 12 months in treated patients. (investor.livanova.com)

The key differentiator in this approval is the system’s proximal hypoglossal nerve stimulation approach. FDA’s summary of safety and effectiveness says the device stimulates the proximal hypoglossal nerve using a six-contact cuff electrode to maintain upper-airway tone during sleep. In the pivotal OSPREY trial, the primary endpoint was AHI responder rate at month 7, defined as at least a 50% drop in AHI and a final AHI below 20. The treatment arm met that mark in 58.2% of patients, versus 13.5% in controls. Median AHI in the treatment group fell from 34.3 at baseline to 11.6 at month 7, and durability data showed a 64.6% responder rate at month 13 in the original treatment arm. (accessdata.fda.gov)

Safety and labeling details are also important. FDA lists contraindications for patients with substantial central or mixed apnea burden, those needing MRI, and certain other conditions that could interfere with implantation or ongoing use. The SSED notes the generator and lead are MR unsafe and would need to be explanted if an MRI is required. Through month 7, FDA reported a combined SAE and SADE incidence of 5.8%, with 3.8% deemed device-related after reclassification of certain surgical intervention events; across 13 months, there were no deaths in OSPREY. (accessdata.fda.gov)

LivaNova is emphasizing access-related distinctions in its launch messaging. In its approval announcement, the company called aura6000 the first and only U.S.-approved hypoglossal nerve stimulation therapy without contraindication or warning language tied to complete concentric collapse, and said there is no requirement for pre-implantation DISE. FDA’s own review supports the DISE point, stating DISE was not required for patient selection, and it confirms that patients with CCC were not excluded, though CCC was not systematically assessed as a separate subgroup. That means the broader positioning appears directionally supported by the label and trial design, but the company’s claims about CCC should still be read with the nuance that FDA did not evaluate outcomes specifically in a confirmed CCC subgroup. (nasdaq.com)

Industry context matters here, too. Inspire’s upper-airway stimulation system already has an established FDA-approved presence in OSA, including an expanded 2023 indication up to AHI 100 and BMI up to 40, but its labeling includes a soft-palate collapse limitation. By contrast, FDA’s aura6000 review found treatment effects were generally consistent across subgroups, including BMI below and above 32, and did not require DISE-based exclusion at enrollment. For sleep specialists and referring clinicians, that could translate into a somewhat different patient-selection workflow if uptake follows the label. (fda.gov)

There is also a broader neuromodulation backdrop worth noting. While aura6000 targets upper-airway control rather than cognition, FDA has recently shown continued openness to implantable neurostimulation systems in other difficult-to-treat conditions. One recent example is Nia Therapeutics’ Smart Neurostimulation System, which received FDA Breakthrough Device designation for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent deficits. According to the company, that fully implantable closed-loop system records neural activity from 60 channels across four brain regions and delivers targeted stimulation to the lateral temporal cortex; in a sham-controlled study in neurosurgical patients with epilepsy and a history of TBI, it improved recall by 19%, while random stimulation showed no benefit. Nia has said it plans to file an IDE in 2026. That does not affect aura6000’s regulatory standing, but it reinforces the larger trend: FDA is increasingly engaging with more sophisticated implantable stimulation platforms, including systems that sense and respond rather than simply deliver fixed therapy. (PharmaShots)

Why it matters: For veterinary professionals, this isn’t a companion-animal regulatory story, but it is relevant as a signal of where implantable neurostimulation and FDA device regulation are moving. The approval shows how companies are trying to expand beyond CPAP-intolerant human sleep apnea patients with more tailored neuromodulation platforms, broader selection criteria, and rechargeable long-life systems. It’s also a reminder that post-approval evidence will matter: FDA has already posted two required post-approval studies for aura6000, suggesting regulators want continued real-world and longer-term follow-up as the product enters practice. The parallel Breakthrough designation for Nia’s TBI-related memory-loss device adds to that picture by showing FDA support not just for airway stimulation, but for newer closed-loop neurotechnology concepts as well. (accessdata.fda.gov; PharmaShots)

What to watch: LivaNova says the currently approved system is a bridge to a next-generation, MRI-compatible device with remote configuration features and an expected first-half 2027 launch, subject to FDA supplement review. Nearer term, watch for publication of fuller OSPREY data, payer coverage decisions, surgeon and sleep-center adoption patterns, and whether the broader labeling around DISE and CCC changes referral behavior in the competitive HGNS market. More broadly, keep an eye on adjacent neuromodulation programs such as Nia’s planned 2026 IDE filing, because progress there would further signal how quickly FDA is moving to evaluate implantable, sensing-enabled neurostimulation systems across multiple indications. (nasdaq.com; PharmaShots)